JP2021513982A5 - - Google Patents

Info

Publication number
JP2021513982A5
JP2021513982A5 JP2020543562A JP2020543562A JP2021513982A5 JP 2021513982 A5 JP2021513982 A5 JP 2021513982A5 JP 2020543562 A JP2020543562 A JP 2020543562A JP 2020543562 A JP2020543562 A JP 2020543562A JP 2021513982 A5 JP2021513982 A5 JP 2021513982A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
heteroaryl
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513982A (ja
JP7368365B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018158 external-priority patent/WO2019161162A1/en
Publication of JP2021513982A publication Critical patent/JP2021513982A/ja
Publication of JP2021513982A5 publication Critical patent/JP2021513982A5/ja
Priority to JP2023176793A priority Critical patent/JP2024009948A/ja
Application granted granted Critical
Publication of JP7368365B2 publication Critical patent/JP7368365B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543562A 2018-02-16 2019-02-15 P300/cbp hat阻害剤及びそれらの使用の方法 Active JP7368365B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023176793A JP2024009948A (ja) 2018-02-16 2023-10-12 P300/cbp hat阻害剤及びそれらの使用の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631596P 2018-02-16 2018-02-16
US62/631,596 2018-02-16
US201862758885P 2018-11-12 2018-11-12
US62/758,885 2018-11-12
PCT/US2019/018158 WO2019161162A1 (en) 2018-02-16 2019-02-15 P300/cbp hat inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023176793A Division JP2024009948A (ja) 2018-02-16 2023-10-12 P300/cbp hat阻害剤及びそれらの使用の方法

Publications (3)

Publication Number Publication Date
JP2021513982A JP2021513982A (ja) 2021-06-03
JP2021513982A5 true JP2021513982A5 (cg-RX-API-DMAC7.html) 2022-02-24
JP7368365B2 JP7368365B2 (ja) 2023-10-24

Family

ID=65685973

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543562A Active JP7368365B2 (ja) 2018-02-16 2019-02-15 P300/cbp hat阻害剤及びそれらの使用の方法
JP2023176793A Pending JP2024009948A (ja) 2018-02-16 2023-10-12 P300/cbp hat阻害剤及びそれらの使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023176793A Pending JP2024009948A (ja) 2018-02-16 2023-10-12 P300/cbp hat阻害剤及びそれらの使用の方法

Country Status (19)

Country Link
US (2) US11274090B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752497B1 (cg-RX-API-DMAC7.html)
JP (2) JP7368365B2 (cg-RX-API-DMAC7.html)
CN (1) CN112218857B (cg-RX-API-DMAC7.html)
AU (1) AU2019220662B2 (cg-RX-API-DMAC7.html)
CA (1) CA3091342A1 (cg-RX-API-DMAC7.html)
DK (1) DK3752497T3 (cg-RX-API-DMAC7.html)
ES (1) ES2989149T3 (cg-RX-API-DMAC7.html)
FI (1) FI3752497T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241225T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068342T2 (cg-RX-API-DMAC7.html)
LT (1) LT3752497T (cg-RX-API-DMAC7.html)
PL (1) PL3752497T3 (cg-RX-API-DMAC7.html)
PT (1) PT3752497T (cg-RX-API-DMAC7.html)
RS (1) RS65966B1 (cg-RX-API-DMAC7.html)
SI (1) SI3752497T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400371T1 (cg-RX-API-DMAC7.html)
TW (1) TW202000658A (cg-RX-API-DMAC7.html)
WO (1) WO2019161162A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019220662B2 (en) * 2018-02-16 2024-06-13 Constellation Pharmaceuticals, Inc. P300/CBP HAT inhibitors
WO2019161157A1 (en) 2018-02-16 2019-08-22 Constellation Pharmceuticals, Inc. P300/cbp hat inhibitors
HRP20241237T1 (hr) * 2019-02-27 2024-12-06 Constellation Pharmaceuticals, Inc. Derivati n-(piridinil)acetamida kao inhibitori p300/cbp hat i postupci za njihovu upotrebu
US20220331304A1 (en) * 2019-07-29 2022-10-20 Constellation Pharmaceuticals, Inc. Compounds for use in treating neurological disorders
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
CN111358951B (zh) * 2020-03-26 2022-06-24 上海交通大学医学院附属上海儿童医学中心 一种使成熟右心室心肌细胞转变为未成熟心肌细胞的方法
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer
WO2025169375A1 (ja) 2024-02-07 2025-08-14 住友ファーマ株式会社 4員環構造で置換された3級アミド誘導体
KR20260099568A (ko) * 2024-12-20 2026-06-29 한미약품 주식회사 Ep300 단백질 분해제 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153226A (en) 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
HUT72440A (en) * 1994-03-31 1996-04-29 Bristol Myers Squibb Co Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them
US7834169B2 (en) 2001-09-25 2010-11-16 Sony Corporation P300 histone acetylase inhibitor
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
CA2605110A1 (en) * 2005-04-20 2006-11-02 Merck & Co., Inc. Benzothiophene derivatives
EP2331499B1 (en) 2008-08-19 2016-09-21 Janssen Pharmaceutica NV Cold menthol receptor antagonists
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
CN103172540B (zh) * 2013-03-18 2015-07-01 潍坊博创国际生物医药研究院 苯甘氨酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
CN105979958A (zh) * 2013-10-11 2016-09-28 基因泰克公司 Cbp/ep300布罗莫结构域抑制剂用于癌症免疫疗法的用途
WO2016044777A1 (en) 2014-09-18 2016-03-24 Abbvie Inc. Hat inhibitors and methods for their use
WO2016044771A1 (en) 2014-09-18 2016-03-24 Abbvie Inc. Hat inhibitors and methods for their use
US20160235716A1 (en) 2014-09-18 2016-08-18 Abbvie Inc. Spirocyclic hat inhibitors and methods for their use
EP3302468A4 (en) 2015-06-01 2019-02-06 The Scripps Research Institute SMALL MOLECULAR ANALOGS OF NEMO BINDING PEPTIDE
WO2017205536A2 (en) 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
CN111050766A (zh) * 2017-07-21 2020-04-21 卡德门企业有限公司 Rho相关含卷曲螺旋蛋白激酶的抑制剂
CN108191748A (zh) * 2018-01-24 2018-06-22 齐鲁师范学院 一种含芳杂环氨基肟类化合物、制备方法及其用途
AU2019220662B2 (en) * 2018-02-16 2024-06-13 Constellation Pharmaceuticals, Inc. P300/CBP HAT inhibitors
WO2019161157A1 (en) 2018-02-16 2019-08-22 Constellation Pharmceuticals, Inc. P300/cbp hat inhibitors

Similar Documents

Publication Publication Date Title
JP7368365B2 (ja) P300/cbp hat阻害剤及びそれらの使用の方法
US20090192200A1 (en) Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
JPWO1999031073A1 (ja) 新規なピリミジン−5−カルボキサミド誘導体
JP2015514780A5 (cg-RX-API-DMAC7.html)
JP2012532112A5 (cg-RX-API-DMAC7.html)
US20090298894A1 (en) Amino acid compounds
JP2002518495A (ja) イルベサルタンの新規なフォーム、それを得る方法およびそれを含む医薬組成物
TW201617319A (zh) (2s,3s)7-氟-2-(4-氟苯基)-3-(1-甲基-1h-1,2,4-三唑-5-基)-4-側氧基-1,2,3,4-四氫喹啉-5-羧酸甲酯之共形成體鹽及其製備方法
US8399668B2 (en) Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides
JP2020517677A5 (cg-RX-API-DMAC7.html)
JP2006507355A5 (cg-RX-API-DMAC7.html)
WO2016016766A2 (en) A process for the preparation of isavuconazonium or its salt thereof
JP6873053B2 (ja) タンパク質脱アセチル化阻害剤の製造方法
JP2017534653A (ja) ブロモドメイン及びエキストラ末端タンパク質の阻害のための方法及び組成物
TW201609679A (zh) 磷脂酸肌醇-3-激酶抑制劑的製造方法
CN105164100A (zh) 用于合成手性犬尿氨酸化合物的方法
JP2023518474A5 (cg-RX-API-DMAC7.html)
JP2024509760A5 (cg-RX-API-DMAC7.html)
JP3160297B2 (ja) ピリミジン誘導体の製造方法
JP2019510801A5 (cg-RX-API-DMAC7.html)
JPWO2018021508A1 (ja) ピラゾール−アミド化合物の製造方法
JP7292517B2 (ja) オキセタン-2-イルメタンアミンの調製のためのプロセスおよび中間体
CN103228648A (zh) (s)-2-氨基-3-(4-(2-氨基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧基)嘧啶-4-基)苯基)丙酸的晶体形式
WO2012090221A1 (en) Novel salts of imatinib
JP2002520321A (ja) 2−アミノ−4−クロロ−1,3,5−トリアジンの製造方法